CJC-1295 + Ipamorelin stack · research pairing
The CJC-1295 + Ipamorelin stack: two receptors, one vial.
The reason CJC-1295 and Ipamorelin are searched as a stack rather than as rivals is mechanistic: they act at two different receptors. CJC-1295 is a GHRH-receptor analog; Ipamorelin is a short, selective ghrelin / growth-hormone-secretagogue-receptor pentapeptide. In laboratory models the canonical growth-hormone-secretagogue design pairs a GHRH-pathway compound with a GHRP-class compound, which is exactly why Titan supplies them as a single blended research vial. This page explains the pairing logic, the no-DAC half-life note, and the documentation standard a blend demands — research framing only, no dosing or human-use guidance.
Why pair them at all
The pairing logic is two-receptor coverage. CJC-1295 engages the GHRH receptor — associated in research models with the amplitude and duration of a growth-hormone pulse. Ipamorelin engages the ghrelin / GHS receptor — associated with initiating a pulse, selectively. Because the two act at different receptors, research protocols study them as a complementary secretagogue pair, not as substitutes. The 'stack' is the canonical model, not an upsell.
CJC-1295 vs Ipamorelin →Why Ipamorelin specifically
Ipamorelin is the selective GHRP in this pairing for a reason researchers note: it is a short pentapeptide studied for a comparatively clean ghrelin-receptor profile relative to older, less-selective secretagogues. Pairing a selective GHRP with a GHRH analog is the rationale behind the standard two-compound secretagogue model — the same logic that separates this from a single-compound approach like the oral MK-677.
MK-677 vs Ipamorelin →DAC vs no-DAC in a blend
'CJC-1295' names two molecules — with DAC (Drug Affinity Complex) and without it (Modified GRF 1-29) — and they carry different masses and research half-lives. In a CJC-1295 + Ipamorelin blend, the no-DAC (Modified GRF 1-29) form is the common pairing because its shorter half-life is studied alongside the pulse-initiating GHRP. The molecular weight on the release sheet — not the label — is what confirms which form is in the vial.
Blend COA red flags →A blend means the COA must prove both
Verifying one peptide is a single mass check; a two-peptide blend is not. The release sheet has to confirm each component's identity by mass and resolve both purities — a single combined purity number quietly hides which half is short or under-represented. Titan's blend ships with a lot-matched in-house release sheet referenced to the lot code on the unit, against an HPLC purity target with identity confirmation by mass.
How to verify a blend COA →How to source the stack
Titan supplies the CJC-1295 + Ipamorelin stack as a single lyophilized blended vial ($119.99) — crypto-only checkout in BTC, USDC, or SOL. The network and wallet are shown before payment and an order ID is logged with support first. One vial, one lot, one release sheet covering both peptides — the documented way to source the pairing rather than buying two unverified singles.
Buy the blend with crypto →Where the research-use line sits
CJC-1295 and Ipamorelin are research compounds. Nothing here is a dosing schedule, a stacking protocol for human use, or a growth, muscle, or anti-aging claim — that marketing language is a compliance red flag, not science. Titan supplies the blend strictly for in-vitro laboratory work, not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use.
See the testing workflow →The detail, in plain terms
Why the pairing is the model, not the upsell.
The stack rests on pharmacology: a GHRH-receptor analog and a selective ghrelin/GHS-receptor pentapeptide act at two different receptors, which is why the literature studies them together. Titan supplies them as one documented blend.
- CJC-1295
- GHRH-receptor analog (~29-residue GHRH(1-29) analog) · with or without DAC · pulse amplitude/duration in models.
- Ipamorelin
- Selective ghrelin / GHS-receptor pentapeptide (5 residues) · pulse-initiating, selectively, in models.
- Why paired
- Two different receptors — the canonical complementary-secretagogue research design.
- Blend form note
- No-DAC (Modified GRF 1-29) is the common CJC form in the pairing — confirm by COA mass.
- Blend COA rule
- The release sheet must confirm BOTH peptides by mass, not one combined purity number.
- Titan stocks
- CJC-1295 + Ipamorelin blended vial, $119.99 — research use only.
Questions researchers ask
Before you order.
- Why are CJC-1295 and Ipamorelin stacked together?
- Because they act at two different receptors. CJC-1295 is a GHRH-receptor analog associated in research models with the amplitude and duration of a growth-hormone pulse; Ipamorelin is a selective ghrelin / GHS-receptor pentapeptide associated with initiating a pulse. The canonical growth-hormone-secretagogue research model pairs a GHRH-pathway compound with a GHRP-class compound, which is why they are studied together rather than chosen between. This is research framing, not a human-use protocol.
- Is the CJC-1295 + Ipamorelin stack different from buying them separately?
- Titan supplies them as a single blended research vial rather than two separate products, because the pairing — not either compound alone — is the standard secretagogue model in the literature. A blend also means one lot-matched release sheet has to confirm both peptides by mass, which is the documentation advantage over sourcing two unverified singles.
- Should the CJC-1295 in the stack be DAC or no-DAC?
- 'CJC-1295' refers to two molecules — with DAC (Drug Affinity Complex) and without it (Modified GRF 1-29) — carrying different masses and research half-lives. The no-DAC (Modified GRF 1-29) form is the common one paired with Ipamorelin in research blends. The molecular weight on the release sheet, not the label, confirms which form is actually in the vial. Titan provides this as research context only.
- How do I verify a CJC-1295 + Ipamorelin blend?
- A blend ships with a lot-matched in-house release sheet referenced to the lot code on the unit, and the certificate must confirm each component's identity by mass — not a single combined purity number. The COA verification guide explains how to read an HPLC/MS release sheet for a blend, including checking that both peptides are confirmed and full-length, before trusting any supplier's documentation.
- Is the CJC-1295 + Ipamorelin stack for human use?
- No. The CJC-1295 + Ipamorelin blend from Titan is sold strictly for in-vitro laboratory research. It is not for human or animal consumption, diagnostic, therapeutic, or preventative use, and no growth, performance, or anti-aging outcome is claimed. Nothing here is a dosing schedule or human-use stacking protocol.